On March 28, 2024, Invivyd, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, and highlighted recent business achievements. The announcement was made through a press release which was furnished as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC. Invivyd reported significant progress, including the emergency use authorization (EUA) granted by the FDA for PEMGARDA, a monoclonal antibody for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. The company anticipates immediate availability of PEMGARDA in the U.S. and is preparing for a full commercial launch. Invivyd leveraged its INVYMAB platform to design VYD2311, the next anti-SARS-CoV-2 monoclonal antibody candidate. Financially, Invivyd ended the year with $200.6 million in...Show More

On March 28, 2024, Invivyd, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, and highlighted recent business achievements. The announcement was made through a press release which was furnished as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC. Invivyd reported significant progress, including the emergency use authorization (EUA) granted by the FDA for PEMGARDA, a monoclonal antibody for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. The company anticipates immediate availability of PEMGARDA in the U.S. and is preparing for a full commercial launch. Invivyd leveraged its INVYMAB platform to design VYD2311, the next anti-SARS-CoV-2 monoclonal antibody candidate. Financially, Invivyd ended the year with $200.6 million in cash and cash equivalents and raised an additional $40.5 million in February 2024 through its At-the-Market facility. The company expects its funds to cover expenses into the fourth quarter of 2024. R&D expenses decreased to $163.6 million in 2023 from $183.6 million in 2022, while SG&A expenses increased slightly to $49.1 million. The net loss for the year was $198.6 million, with a basic and diluted net loss per share of $1.81. Invivyd's CEO, Dave Hering, expressed pride in the company's achievements and focus on executing the commercial launch plan for PEMGARDA.